M. Inchauspé

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

H. van de Velde, S. Harrison, T. Facon, 2021, British journal of haematology.

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

P. Richardson, H. van de Velde, P. Moreau, 2022, Haematologica.

Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis

P. Richardson, S. Harrison, T. Facon, 2019, Clinical Lymphoma, Myeloma & Leukemia.